共 50 条
- [1] Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsPEDIATRICS, 2016, 138 (02)Moreira, Edson D., Jr.Block, Stan L.Ferris, DaronGiuliano, Anna R.Iversen, Ole-ErikJoura, Elmar A.Kosalaraksa, PopeSchilling, AndreaVan Damme, PierreBornstein, JacobXavier Bosch, F.Pils, SophieCuzick, JackGarland, Suzanne M.Huh, WarnerKjaer, Susanne K.Qi, HongHyatt, DonnaMartin, JasonMoeller, ErinRitter, MichaelBaudin, MartineLuxembourg, Alain
- [2] A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in menVACCINE, 2016, 34 (35) : 4205 - 4212Van Damme, PierreMeijer, Chris J. L. M.Kieninger, DorotheeSchuyleman, AnneThomas, StephaneLuxembourg, AlainBaudin, Martine
- [3] Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology GuidelineJOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (02)Min, Kyung-JinKwon, Sang-HoonKim, KidongKim, SunghoonKim, Hyun JungSeong, Seok JuSong, Yong JungLee, Keun HoLee, Shin-WhaLee, Jeong-WonChang, Suk-JoonJu, WoongKim, Young-TakLee, Jae-Koran
- [4] Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studiesHUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)Giuliano, Anna R.Palefsky, Joel M.Goldstone, Stephen E.Bornstein, JacobDe Coster, IlseGuevara, Ana MariaMogensen, OleSchilling, AndreaVan Damme, PierreVandermeulen, CorinneEllison, Misoo C.Group, ThomasKaplan, SusanLin, JianxinBonawitz, RachaelLuxembourg, Alain
- [5] Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III StudiesONCOLOGIST, 2013, 18 (03): : 273 - 280Hurwitz, Herbert I.Douglas, Pamela S.Middleton, John P.Sledge, George W.Johnson, David H.Reardon, David A.Chen, DafengRosen, Oliver
- [6] Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?PREVENTIVE MEDICINE, 2021, 144Kuter, Barbara J.Garland, Suzanne M.Giuliano, Anna R.Stanley, Margaret A.
- [7] Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from NepalHUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (07) : 2149 - 2157Saluja, TarunGiri, Bishnu RathChaudhary, ShipraTamrakar, DipeshKanodia, PiushPalkar, SonaliVemula, SridharChinaworapong, SuchadaKim, BomiGupta, Birendra PrasadKyoung Jo, SueAspinall, SanetRai, Ganesh KumarSteele, DuncanKim, Jerome H.Wartel, T. AnhSahastrabuddhe, Sushant
- [9] Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)CLINICAL CANCER RESEARCH, 2024, 30 (09) : 1768 - 1777Sheth, Sangini S.Oh, Ji EunBellone, StefaniaSiegel, Eric R.Greenman, MichelleMutlu, LeventMcnamara, BlairPathy, ShefaliClark, MitchellAzodi, MasoudAltwerger, GaryAndikyan, VaagnHuang, GloriaRatner, ElenaKim, Daniel J.Iwasaki, AkikoLevi, Angelique W.Buza, NataliaHui, PeiFlaherty, SeanSchwartz, Peter E.Santin, Alessandro D.
- [10] Genotype analysis of rotaviruses isolated from children during a phase III clinical trial with the hexavalent rotavirus vaccine in ChinaVIROLOGICA SINICA, 2023, 38 (06) : 889 - 899Zou, WenqiYu, QingchuanLiu, YanLi, QingliangChen, HongGao, JiameiShi, ChenWang, YingChen, WeiBai, XuanYang, BiaoZhang, JiuweiDong, BenRuan, BoZhou, LiuyifanXu, GelinHu, ZhongyuYang, Xiaoming